Bart DeCorte
Janssen Pharmaceutica
19 Papers
127 Citations
Bart DeCorte is an academic researcher from Janssen Pharmaceutica. The author has contributed to research in topics: δ-opioid receptor & Inverse agonist. The author has an hindex of 6, co-authored 19 publications. Previous affiliations of Bart DeCorte include Johnson & Johnson Pharmaceutical Research and Development.
Chat about Author
Papers
Patent
Tricyclic delta-opioid modulators
Steven J. Coats,Scott L. Dax,Bart DeCorte,Li Liu,Mark McDonnell,Mcnally James J +5 more
- 21 Dec 2005
TL;DR: In this paper, the delta opioid receptor modulators were used to treat mild to severe pain and various diseases using compounds of the invention, which relates to tricyclic δ-opioid modulators.
28
Novel triazole based inhibitors of Ras farnesyl transferase
Ashis K. Saha,Liu Li,Richard L. Simoneaux,Bart DeCorte,Christophe Meyer,Stacy Skrzat,Henry J. Breslin,Michael Joseph Kukla,Dave W. End +8 more
TL;DR: A novel series of potent inhibitors of Ras farnesyl transferase possessing a 1,2,4-triazole pharmacophore is described and was subsequently optimized to in vitro IC(50) value of less than 1nM.
24
1,2,3,4-Tetrahydroquinoline-containing αvβ3 integrin antagonists with enhanced oral bioavailability
Shyamali Ghosh,Rosemary J. Santulli,William A. Kinney,Bart DeCorte,Liu Li,Joan M. Lewis,Jef C. Proost,Gregory C. Leo,John A. Masucci,William Hageman,Andrew S. Thompson,Ian Chen,Reiko Kawahama,Robert W. Tuman,Robert A. Galemmo,Dana L. Johnson,Bruce P. Damiano,Bruce E. Maryanoff +17 more
TL;DR: In this article, the quinoline ring reduction in an α-vβ3 antagonist yielded a 1,2,3,4-tetrahydro derivative as two diastereomers, the four isomers of which were separated by sequential chiral HPLC.
18
Patent
Tricyclic opioid modulators
Bart DeCorte,Li Liu,Mark McDonnell,Mcnally James J +3 more
- 15 Jun 2006
TL;DR: In this paper, the authors describe various formulations and methods of treating mild to severe pain and various diseases using compounds of the Formula (I) invention, such as delta and mu opioid receptor modulators.
17
Novel Triazole Based Inhibitors of Ras Farnesyl Transferase.
Ashis K. Saha,Liu Li,Richard L. Simoneaux,Bart DeCorte,Christophe Meyer,Stacy Skrzat,Henry J. Breslin,Michael Joseph Kukla,Dave W. End +8 more
TL;DR: In this article, a series of potent inhibitors of Ras farnesyl transferase possessing a 1,2,4-triazole pharmacophore was described, which were discovered from a parallel synthesis effort and were subsequently optimized to in vitro IC50 value of less than 1 nM.
13